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Down-regulatory mechanism of mammea
E/BB from Mammea siamensis seed extract
on Wilms’ Tumor 1 expression in K562 cells
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Colleen A. Sweeney4,6* and Songyot Anuchapreeda5,7*
Abstract
Background: Wilms’ tumor 1 (WT1) is a biological marker for predicting leukemia progression. In this study, mammea E/BB,
an active compound from Saraphi (Mammea siamensis) seed extract was examined for its effect on down-regulatory
mechanism of WT1 gene expression, WT1 protein and mRNA stability, and cell proliferation in K562 cell line.
Methods: M. siamensis seeds were obtained from the region of Chiang Mai (North of Thailand). Mammea E/BB was
extracted from seeds of M. siamensis. WT1 protein expression and stability were evaluated by Western blot analysis. WT1
mRNA stability was assessed by qRT-PCR. WT1-DNA binding and WT1 promoter activity were assayed by ChIP assay and
luciferase-reporter assay, respectively. Cell cycle arrest was studied by flow cytometry.
Results: Treatment with mammea E/BB led to down-regulation of WT1 expression. The suppression of WT1 expression
did not involve protein and mRNA degradation. Rather, WT1 protein was down-regulated through disruption
of transcriptional auto-regulation of the WT1 gene. Mammea E/BB inhibited WT1-DNA binding at the WT1
promoter and decreased luciferase activity. It also disrupted c-Fos/AP-1 binding to the WT1 promoter via
ERK1/2 signaling pathway and induced S phase cell cycle arrest in K562 cells.
Conclusion: Mammea E/BB had pleotropic effects on kinase signaling pathways, resulting in inhibition of
leukemia cell proliferation.
Keywords: Mammea E/BB, Mammea siamensis, WT1, AP-1, ERK1/2, Cell cycle arrest, K562 cells
Background
Mammea siamensis (Miq.) T. Anders is a Thai medicinal
plant belonging to the family of Guttiferae, and is known
in Thai as “Saraphi” [1]. Previous phytochemical studies of
Mammea have led to the isolation and structural deter-
mination of coumarins (mammea, surangin, therapin,
calanone, mammeanoyl, etc.) found in the root, leaf, twig,
stem, bark, flower, and seed of M. siamensis, M. harman-
dii, M. americana, M. longifolia, and other species of
Mesua and Calophyllum [2–10]. Coumarins are well-
known natural products that have been shown to have
various biological activities, such as insecticidal [11],
antioxidant [5, 12, 13], antibacterial [5], antifungal [14],
anti-malarial [15], anti-HIV [16], and anticancer activities
[4, 7, 10, 12, 13]. A previous study reported the isolation
and structural determination of phenolic compounds from
M. siamensis seeds, including siamensone A, surangin B,
mammea E/BB (Fig. 1), and δ-tocotrienol [6]. Recently,
compounds from the flowers of M. siamensis were found
to exert antiproliferative actions through apoptotic cell
death in leukemia cells [10].
The Wilms’ tumor 1 (WT1) gene is located at chromo-
some 11p13 and encodes a 48–57 kDa WT1 protein that
functions as a DNA-binding transcription factor in-
volved in growth regulation, and is necessary for the in-
duction of cell differentiation [17]. WT1 has been
purported to have both oncogenic and tumor suppressor
functions. Low levels of WT1 protein expressions have
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been found in normal blood cells, while high levels of
WT1 protein have been found in leukemia patients [18].
Previously, pure curcumin was shown to repress WT1
gene expression in both primary and leukemic cells [19].
In addition, Semsri et al. reported that pure turmeric
curcumin affected WT1 protein-promoter binding and
decreased WT1 mRNA and protein levels through in-
hibition of the PI3K/PKCα/JNK pathway in K562 cells
[20]. Moreover, expression of the WT1 gene and its
product has been used as biological markers for diagno-
sis and evaluation of the prognosis in leukemia and min-
imal residual disease (MRD) [18, 21]. A previous study
revealed that mammea E/BB also suppressed WT1 pro-
tein expression when compared to surangin A and sur-
angin C [22]. However, the down-regulatory mechanism
was unknown. The current study therefore aimed to
examine the inhibitory mechanism of mammea E/BB on
WT1 gene expression, WT1 protein and mRNA stability,
and cell proliferation in K562 cell line.
Methods
Materials
M. siamensis seeds were collected from Chiang Mai
University, Amphoe Muang, Chiang Mai province,
Thailand in May 2010. The plant material used in this
study was identified by Mr. James Franklin Maxwell. A
voucher specimen (J.F. Maxwell, No.92-70) is deposited
in the CMU herbarium, Faculty of Science, Chiang Mai
University, Chiang Mai, Thailand. RPMI-1640, fetal bo-
vine serum, L-glutamine, penicillin/streptomycin, Quick-
Change Site Mutagenesis Kit, and HRP-conjugated goat
anti-rabbit IgG were purchased from Invitrogen™ Life
(Carlsbad, CA, USA). MTT dye and StaphA cells were
purchased from Sigma-Aldrich (St Louis, MO, USA).
Trypan blue dye solution was purchased from
AMRESCO® (Solon, OH, USA). Rabbit anti-WT1 and
rabbit anti-GAPDH was purchased from Santa Cruz Bio-
technology (CA, USA). Rabbit anti-p-ERK1/2 was pur-
chased from New England BioLabs (Beverly, MA, USA).
Mouse anti-cyclin B and Mouse anti-cyclin A were pur-
chased from BD Transduction Laboratories™ (USA).
Mouse anti-CDK1 (cdc2) was purchased from Abcam®
(MA, USA). Rabbit anti-c-Fos and PathScan® Intracellu-
lar Signaling Array Kit (Chemiluminescent Readout)
were purchased from Cell Signaling Technology® (Dan-
vers, MA, USA). HRP-conjugated anti-mouse IgG, Go
Taq® DNA Polymerase, Dual-Luciferase Reporter Assay
Kit, and β-galactosidase Assay Kit were purchased from
Promega (WI, USA). Enhanced chemiluminescence
detection kit and Dream Taq Green PCR master mix
were purchased from Thermo Scientific (Miami, USA).
E.Z.N.A.® Total RNA Kit I was purchased from Omega
bio-tek (Norcross, GA, USA). RevertAid First Strand
cDNA Synthesis Kit was purchased from Thermo
Fig. 1 Chemical structure of Mammea E/BB
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scientific (EU). Cycloheximide (CHX) and actinomycin
D were purchased from Calbiochem (USA). Qiaquick
PCR kit was purchased from Qiagen (CA, USA).
General experimental procedures
Optical rotations were measured with a JASCO P-1020 po-
larimeter. 1D and 2D NMR spectra were recorded using a
Bruker AVANCE 400 NMR spectrometer. Chemical shifts
(δ) are expressed in ppm with reference to the solvent sig-
nals. UV spectra were measured using a SHIMADZU UV-
2450 spectrophotometer.
Extraction and isolation of mammea E/BB
Mammea E/BB was purified from seeds of M. siamensis
using column chromatography, extraction, and isolation as
previously described [22]. Mammea E/BB was obtained as
a pale yellowish gum with [α]D
27 −65.7° (c = 0.40, MeOH).
The UV spectra of mammea E/BB exhibited absorption
maxima bands at 337 and 265 nm; these are character-
istic for coumarin [23]. The absolute stereochemistry at
C-1’ and C-2′′′ was assigned to be S from its negative
optical rotation value [12]. The mammea E/BB identity
was confirmed by comparison of the 1H and 13C
NMR spectra data (Additional file 1: Figure S1 and
Additional file 2: Figure S2) with those reported in
the literature [24, 25].
Cells and cell culture conditions
The K562 cell line, a model of WT1-overexpressing
leukemic cells, was cultured in RPMI-1640 medium sup-
plemented with 10 % fetal bovine serum, 1 mM L-glu-
tamine, 100 units/ml penicillin, and 100 μg/ml
streptomycin, and incubated under 95 % relative humid-
ity with 10 % CO2 at 37 °C.
MTT assay
The cytotoxicity of mammea E/BB was evaluated using
the MTT assay. Briefly, K562 cells (1.0 × 104 cells/well)
were cultured in 96 well plates containing 100 μl medium
prior to treatment for 24 h. After that, 100 μl of fresh
medium containing various concentrations (0–116 μM) of
the test compound were added to each well and incubated
for 72 h. The MTT dye solution was added and the per-
cent cell viability, IC50, and IC20 values were calculated as
previously described [22].
Trypan blue exclusion assay
Cell proliferation was measured by the trypan blue exclu-
sion method. Cells were treated with various concentra-
tions of mammea E/BB for 72 h. Then cells and 0.4 %
trypan blue dye were mixed and counted using a light
microscrope. All experiments were performed in triplicate.
Protein extraction and Western blotting
K562 cells were treated with mammea E/BB for 72 h,
after which the cells were collected, washed twice with
cold PBS, and lysed with cold RIPA buffer (50 mM Tris-
HCl, 150 mM NaCl, 1 % Triton X-100, 0.5 mM EDTA,
0.1 % SDS, and 0.001 % protease inhibitor cocktail) for
whole protein extraction. Whole protein lysates (25 μg)
were loaded onto 12 % SDS-PAGE and then transferred
to PVDF membranes. Membranes were blocked with
5 % skim milk and probed with rabbit anti-WT1, rabbit
anti-p-ERK1/2, mouse anti-cyclin B, mouse anti-cyclin
A, and mouse anti-CDK1 (cdc2) at 1:1,000 dilution.
Rabbit anti-GAPDH at a dilution of 1:1,000 was used for
protein loading control. The reaction was followed by
HRP-conjugated goat anti-rabbit IgG at 1:10,000 dilution
and HRP-conjugated anti-mouse IgG at 1:10,000 dilu-
tion. Proteins were visualized using an enhanced chemi-
luminescence detection kit and the chemiluminescent
signals detected using an Alpha Innotech gel imaging
system (Cell Biosciences Inc., CA, USA). Densitometry
was performed using Alpha Innotech software. The band
density of the loading control was used to normalize the
band densities of proteins of interest to obtain the rela-
tive normalized expression level as compared to the ex-
posed control.
RNA isolation and reverse transcription PCR analysis
K562 cells were treated with mammea E/BB and the cell
pellets were collected. The pellets were washed twice with
cold PBS and isolated by E.Z.N.A.® Total RNA Kit I ac-
cording to the manufacture’s protocol. The cDNA (1 μg)
was synthesized from total RNAs using a RevertAid First
Strand cDNA Synthesis Kit with random hexamer primers
according to the manufacture’s instructions. RT-PCR ana-
lysis was carried out with a Mastercycler® personal (Eppen-
dorf, CA, USA) instrument with Dream Taq Green PCR
master mix probe-based chemistry for WT1 and GAPDH.
Protein degradation and mRNA half-Life analysis
K562 cells were incubated (0, 3, 6, 12, and 24 h) with or
without 5 μM MG132 (proteasome inhibitor) and con-
firmed by 50 μg/ml cycloheximide (CHX) in the pres-
ence or absence of 3.5 μM of mammea E/BB. The WT1
mRNA stability of K562 cells was assessed with 4 μM
actinomycin D in the presence or absence of 3.5 μM
mammea E/BB.
Chromatin immunoprecipitation (ChIP) assay
The concept of chromatin immunoprecipitation or ChIP
is an experimental form of immunoprecipitation used to
investigate the interaction between proteins and DNA in
the cell [26]. Briefly, cells were treated with 3.5 μM
mammea E/BB for 72 h then crosslinked with 1 % for-
maldehyde for 10 min, followed by addition of 0.125 M
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glycine to stop the crosslinking. Cells were suspended in
cell lysis buffer (5 mM PIPE, 85 mM KCl, 1 % NP40, and
protease inhibitors), incubated on ice for 15 min and centri-
fuged at 5,000 rpm at 4 °C for 5 min. The nuclei pellet was
resuspended in lysis buffer (50 mM Tris-HCl, pH 8.0,
10 mM EDTA, 1 % SDS, and protease inhibitors) and incu-
bated on ice for 10 min before sonication. The chromatin
lysate was precleared with StaphA cells before immunopre-
cipitation at 4 °C overnight. Antibodies included WT1 (C-
19), c-Fos, and normal rabbit IgG as a negative control. On
the following day Staph A cells were added to precipitate
the IgG/protein/DNA complex. The StaphA cell pellets
were washed extensively, followed by elution and reversal
of protein-DNA crosslinking. The protein was removed
from the DNA lysate using the Qiaquick PCR kit. Standard
PCR was performed on the precipitated DNA template
using Go Taq® DNA Polymerase.
Primer design
The human WT1 promoter sequence was obtained from
NCBI, accession # U77682. Primer design for the WT1
promoter region utilized Primer3 Input (version 0.4.0),
UCSC Genome Browser and Vector NTI advance 10:
WT1 promoter primer sequence No.1 consisted of the for-
ward primer (CTGAACGGACTCTCCAGTG) and reverse
primer (CGCTGCCTTGAACTCCTTAC); WT1 promoter
primer sequence No.2 consisted of the forward primer
(GGCCCCTCTTATTTGAGCTT) and reverse primer
(CAAGAGGAA GTCCAGGATCG).
Promoter luciferase-reporter assay
WT1 promoter vectors were a kind gift from Professor Dr.
Takashi Murate (Department of Medical Technology,
Nagoya University Graduate School of Heath Sciences,
Japan). The WT1 promoter sequence, including the WT1
and c-Fos/AP-1 binding site, and 301 bp reporter constructs
was inserted into the pGL3 basic vector. For the mutant
pGL3 construct, core nucleotides of a potential WT1 bind-
ing site were altered using a Quick-Change Site Mutagenesis
Kit with PCR primers for the WT1 consensus sequence lo-
cated at -50 to-39; GTGTGGGAGCC [27] was mutated to
ATATGATATCA. K562 cells were co-transfected with the
construct vector and β-galactosidase (β-Gal) for 24 h and
then treated with mammea E/BB. Co-transfected cells were
lysed with lysis buffer. Luciferase activity of the lysis solution
was measured using a Dual-Luciferase Reporter Assay Kit,
β-galactosidase Assay Kit and a GloMax 96 Microplate
Luminometer with dual injections (Promega, USA).
Intracellular signaling array
The intracellular signaling pathway involved in leukemic
cell growth inhibition after treatment was determined using
a PathScan® Intracellular Signaling Array Kit (Chemilumin-
escent Readout).
Cell cycle analysis
Cell cycle analysis was done via flow cytometry using
propidium iodide (PI), which represents the content of
nuclear DNA. K562 cells (1 × 105 cells/ml) were cultured
in complete RPMI-1640 medium with or without mam-
mea E/BB for 72 h. After treatment, cells were washed
twice with ice-cold PBS and prepared as a single-cell
suspension. Then, the cells were fixed with ice-cold 70 %
absolute ethanol for 30 min and harvested by centrifuga-
tion. The cell pellets were then washed with ice-cold
PBS and stained with PI solution (0.1 % triton X-100,
8 μg/ml RNase A, 2 mM EDTA, and 20 μg/ml PI) in the
dark at 4 °C. Thereafter, the red fluorescence was mea-
sured on a BD FACSCaibur flow cytometer (Becton
Dickinson, San Jose, CA, USA). A minimum of 50,000
events was collected per sample. The data were analyzed
using FlowJo 7.6.5 software.
Statistical analysis
All the data were expressed as the mean ± standard devi-
ation (SD) or mean ± standard error of mean (SEM) from
triplicate samples of three independent experiments. The
statistical differences between the means were determined
using one-way ANOVA. The differences were considered
significant when the probability value obtained was found
to be less than 0.05 (p < 0.05).
Results
Mammea E/BB decreased WT1 protein levels and total
cell number with increasing time and dose in K562 cells
The mammea E/BB displayed cytotoxic effects in K562
cells, with an IC50 value of 24.1 ± 2.2 μM, and was non-
cytotoxic at the IC20 value of 3.7 ± 0.2 μM (Additional file 3:
Figure S3). The activity of mammea E/BB on WT1 protein
expression was examined by Western blotting using a non-
cytotoxic dose (3.5 μM). Treatment of K562 cells with
mammea E/BB for 24, 48, and 72 h decreased WT1 protein
levels as compared to the vehicle control (Fig. 2a and b).
Total viable cell numbers at 24, 48, and 72 h were also
found to decrease with time. There were no differences in
the numbers of dead cells (dead cells accounted for less
than 10 %) at each time point between vehicle control and
mammea E/BB treatment (Fig. 2c).
The concentrations used for mammea E/BB decreased
WT1 protein levels (Fig. 3a and b) and total cell numbers
(Fig. 3c).
Mammea E/BB induced S phase cell cycle arrest in K562
Mammea E/BB treatments led to a decline in K562
leukemia cell number without increasing the number of
dead cells, suggesting that growth inhibition was mainly
through cell cycle arrest. Then, cell cycle arrest was then
determined after mammea E/BB treatment by flow
cytometry. Indeed, mammea E/BB treatment (3.5 μM)
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Fig. 2 Inhibitory effects of mammea E/BB on WT1 protein levels and total cell number in K562 cells. a WT1 protein levels in K562 cells treated with
3.5 μM mammea E/BB for 24, 48, and 72 h, detected by Western blotting. GAPDH was used as a loading control. b The protein levels presented as the
percentage of vehicle control (0.006 % DMSO alone without the mammea E/BB in the culture medium), analyzed with the scanning densitometer.
c The total survival and dead cell number of K562 cells after treatment at various times as determined by the trypan blue exclusion method. Data are
the mean value ± SEM of three independent experiments. Asterisks (*) denote values that were significantly different from the vehicle control (p < 0.05)
Fig. 3 Inhibitory effects of mammea E/BB on WT1 protein levels and total cell number in K562 cells. K562 cells were treated with various concentrations
(0.125–4.5 μM) of mammea E/BB for 72 h. a WT1 protein levels were detected by Western blotting. GAPDH was used as a loading control. b The protein
levels presented as the percentage of vehicle control (0.008 % DMSO alone without the mammea E/BB in the culture medium), analyzed with scanning
densitometer. c The total survival and dead cell number of K562 cells after treatment with various concentrations of mammea E/BB, determined by the
trypan blue exclusion method. Data are the mean value ± SEM of three independent experiments. Asterisks (*) denote values that were significantly
different from the vehicle control (p< 0.05)
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led to a significant accumulation of K562 cells in the S
phase of the cell cycle (Fig. 4a and b). Furthermore, cell
cycle checkpoint proteins (cyclin A, cyclin B, and cdc2)
at the S and G2/M phases were significantly decreased
(Fig. 4c and d).
Effect of mammea E/BB on WT1 protein and WT1 mRNA
stability
To determine whether mammea E/BB has any effect on
WT1 protein stability, a time course experiment was per-
formed with the protein synthesis inhibitor, 5 μM MG123
and 50 μg/ml cyclohexamide (CHX). WT1 protein expres-
sion decreased after treatment with mammea E/BB in the
presence or absence of MG132, indicating that the down-
regulation of WT1 protein by mammea E/BB was likely
not through proteasomal degradation pathways (Fig. 5a, b,
and c). In addition, the WT1 protein’s half-life was exam-
ined using the protein synthesis inhibitor, cycloheximide
(CHX). The half-life of WT1 protein after mammea E/BB
treatment was not significantly different from that of the
vehicle control, suggesting that mammea E/BB does not
accelerate WT1 protein degradation (Fig. 5d, e, and f).
WT1 mRNA stability was then examined using actinomy-
cin D (Act D) treatment in the presence or absence of
mammea E/BB. The mammea E/BB treatment did not sig-
nificantly alter the decay of WT1 mRNA (Fig. 6a and b).
Collectively, the results strongly suggest that WT1 repres-
sion by mammea E/BB is not through accelerated WT1
protein or mRNA degradation.
Mammea E/BB attenuates WT1 auto-regulation
Mammea E/BB was next examined for its impact on the
transcriptional regulation of the WT1 gene using the
ChIP assay. WT1 is known to drive its own transcription
using an auto-regulatory mechanism. The WT1 pro-
moter has been found to contain one AP-1 consensus
Fig. 4 Mammea E/BB treatment induced S phase cell cycle arrest in K562 cells. a Cell cycle analysis profile after incubation with 3.5 μmol/L
mammea E/BB for 72 h, using flow cytometry. b Percentage of sub G1, G0/G1, S, and G2M cell populations of the K562 cells after treatment with
mammea E/BB for 72 h are presented and compared to the vehicle control group (VC). c Cyclin B, cyclin A, and cdc2 protein levels in K562 cells
treated with various concentrations (1.5, 2.5, and 3.5 μM) of mammea E/BB for 72 h, detected by Western blotting. GAPDH was used as a loading
control. d The protein levels presented as the percentage of vehicle control (0.006 % DMSO alone without the mammea E/BB in the culture
medium), analyzed with a scanning densitometer. The percentages of cells in each phase and protein levels are represented as mean ± SEM of
three independent experiments. Asterisks (*) denote values that were significantly different from the vehicle control (p < 0.05)
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sequence, TGAGTGA, at +144 to +150. Treatment of
K562 cells with 3.5 μM mammea E/BB for 72 h could sig-
nificantly inhibit WT1 binding to its own promoter, by up
to 75 % (Fig. 7a and b). Mammea E/BB also disrupted c-
Fos/AP-1 binding to the WT1 promoter by 50 % as com-
pared to the vehicle control by standard PCR.
The minimal promoter element essential for WT1 gene
expression is the WT1 proximal promoter (-301 bp) [20].
The WT1 (-50 to -39) consensus binding site is included
in this proximal promoter element (Fig. 7c). Transfection
of this 301 bp construct, contained within the pGL3 re-
porter vector into K562 cells, demonstrated high luciferase
activity in vehicle control treated cells and a diminished re-
sponse with the various concentrations of mammea E/BB
(1.5, 2.5, and 3.5 μM) treated K562 cells (Fig. 7d). As a
control, a reporter construct containing a mutated WT1
binding site was included. The mutant vector did not show
significantly increased activity compared to the empty
pGL3 vector, demonstrating that this assay is mostly
driven by WT1 binding.
Fig. 6 Effect of mammea E/BB on WT1 mRNA stability. To investigate the effect of mammea E/BB on WT1 mRNA stability, K562 cells were treated
with 4 μM actinomycin D (Act D) in the presence or absence of 3.5 μM mammea E/BB for 0, 3, 6, 9, and 12 h and WT1 mRNA was assayed by
Taqman qRT-PCR as shown in a. The WT1 mRNA levels from three independent experiments were quantified and are shown in b. GAPDH was
used as an internal control. Data are the mean value ± SEM of three independent experiments
Fig. 5 Effect of mammea E/BB on WT1 protein stability. To investigate the effect of mammea E/BB on protein stability, K562 cells were treated with
3.5 μM mammea E/BB in the presence or absence of 5 μM MG132 for 6 h and assessed by immunoblotting. a WT1 protein levels from three
independent experiments were quantified and are shown in b. c The effect of 3.5 μM mammea E/BB on WT1 protein levels was examined
in the presence or absence of 5 μM MG132 for 0, 3, 6, 12, and 24 h. The relative protein levels were analyzed with a scanning densitometer.
The relation of WT1 protein levels to mammea E/BB and mammea E/BB +MG132 were compared to the vehicle control and the MG132 control,
respectively. d, e WT1 protein levels of K562 cells after treated with 50 μg/ml cycloheximide (CHX) in the absence or presence of 3.5 μM mammea
E/BB for 0, 3, 6, 12, and 24 h were quantified and are shown in f. The relative protein levels were analyzed with a scanning densitometer and
compared to the CHX control. GAPDH was used as an internal control. Data are the mean value ± SEM of three independent experiments
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Mammea E/BB decreases p-ERK1/2 (Thr202/Tyr204) in
K562 cells
To gain insight into the impact of mammea E/BB on cel-
lular signaling, a kinase signaling array was used to
examine the phosphorylation/activation state of various
key kinases. In this experiment, K562 cells were treated
with non-cytotoxic doses of mammea E/BB (3.5 μM) for
72 h. As shown in Fig. 8, mammea E/BB strongly
decreased p-ERK1/2 (Thr202/Tyr204) in K562 cells
(Fig. 8a). To confirm the signaling array results, p-ERK1/
Fig. 7 Mammea E/BB treatment attenuated WT1 - DNA binding to the proximal WT1 promoter and WT1 promoter activity. a K562 cells were treated
with 3.5 μM mammea E/BB for 72 h and ChIPs were performed. Chromatin lysates were immunoprecipitated with antibodies to WT1, c-Fos/AP-1, Pol II
(positive control) or IgG (negative control). ChIP lysates and 1:50 dilution of input were assayed by standard PCR using primers containing the consensus
sequence for WT1 located at the WT1 proximal promoter. The WT1 immunoprecipitated lysates from mammea E/BB or vehicle control treatment were
analyzed by SYBR green RT-PCR and graphed as relative DNA enrichment over 1:50 input as percentage of vehicle-treatment as shown in b. For WT1
promoter reporter activity, K562 cells were transfected with the pGL3_basic luciferase reporter (Luc) vector containing 301 bp of the wild
type and mutant WT1 proximal promoter (c) followed by 1.5, 2.5, and 3.5 μM or vehicle treatment for 72 h. WT1or a mutant construct
was used to transfect for 24 h and then assayed for firefly luciferase and β-galactosidase (β-Gal) activities. Site directed mutagenesis of
the WT1 consensus sequence (-50 to -39) abrogated the WT1 promoter activity compared to the wild type WT1 promoter construct
(301 bp WT1). The firefly luciferase and β-galactosidase activities were assayed and relative activities were graphed compared to the pGL3 basic vector
(d). Experiments were performed a minimum of three times and representative graphs are shown. Data are the mean value ± SD of three independent
experiments. Asterisks (*) denote values that were significantly different from the vehicle control (p < 0.05)
Fig. 8 Effect of mammea E/BB on p-ERK1/2 in K562 cells. a K562 cells were treated with 3.5 μMmammea E/BB for 72 h using a human phospho-kinase array
kit. Cells were treated with various concentrations for 72 h. b The p-ERK1/2 protein levels of K562 cells were detected by Western blotting. The levels of WT1
protein expression were assessed by immunoblotting; GAPDH was used as a loading control. c The protein levels were analyzed with a scan densitometer
and the graphs were plotted as the percentage of vehicle control (0.003 % DMSO alone without the mammea E/BB in the culture medium). Data are the
mean value ± SEM of three independent experiments. Asterisks (*) denote values that were significantly different from the vehicle control (p< 0.05)
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2 phosphorylation was examined with conventional
Western blotting following mammea E/BB treatment of
K562 cells (Fig. 8b and c). Mammea E/BB treatment led
to a significant decrease in ERK1/2 phosphorylation.
Discussion
To date, saraphi (M. siamensis) has been used in Thai folk
medicine remedies with limited scientific knowledge, espe-
cially regarding its biological activity in leukemic cells. In
this study, mammea E/BB (the active compound in M. sia-
mensis seeds) was examined for its down-regulatory mech-
anism to suppress leukemic cell proliferation via inhibiting
WT1 protein expression. Mammea E/BB has been re-
ported to impact cancer cells [28]. It is an important active
compound in the nonpolar part of M. siamensis seed ex-
tract. The results of the present study demonstrate that
mammea E/BB inhibited cell proliferation and repressed
WT1 expression in the human leukemia K562 cell line.
The activities of mammea E/BB on WT1 protein ex-
pression and total viable cell number were found to de-
crease with increasing time and dose by Western blotting
and trypan blue exclusion method, respectively. There was
no difference in the number of dead cells (dead cells ac-
counting for less than 10 %) at each time point between
the vehicle control and mammea E/BB treatment.
The effect of various concentrations of mammea E/BB
was examined and found to decrease WT1 protein levels
in response to 0.125 to 4.5 μM by Western blotting.
Moreover, the total cell number was significantly de-
creased at 72 h by 61.3 ± 8.9 to 89.2 ± 0.8 %, as com-
pared to the vehicle control. The dead cells accounted
for less than 10 %. Mammea E/BB treatments led to a de-
cline in K562 leukemia cell number without increasing
the number of dead cells, suggesting that growth inhib-
ition is mainly through cell cycle arrest. Thus, the effect of
mammea E/BB on cell cycle progression was investigated.
Indeed, mammea E/BB treatment (3.5 μM) led to a signifi-
cant decline in K562 cells in the S phase of the cell cycle
as assessed by flow cytometry. Furthermore, the proteins
related to S and G2/M phase control were determined. It
was found that cell cycle checkpoint proteins (cyclin A,
cyclin B, and cdc2) at the S and G2/M phases were signifi-
cantly decreased in a dose-dependent manner.
This study next examined whether WT1 down-regulation
by mammea E/BB was through effects on protein or mRNA
degradation pathways. K562 cells occurred treated with
3.5 μM mammea E/BB (IC20) for 24 h in the presence or
absence of the proteasome inhibitor MG132. WT1 protein
expression decreased similarly after treatment with mam-
mea E/BB in the presence or absence of MG132, indicating
that mammea E/BB-mediated down-regulation of WT1
protein was likely not through proteasomal degradation
pathways. In addition, WT1 protein half-life was examined
using the protein synthesis inhibitor, cycloheximide (CHX).
The half-life of WT1 protein after mammea E/BB treatment
was not significantly different as compared to the vehicle
control, suggesting that mammea E/BB does not accelerate
WT1 protein degradation. WT1 mRNA stability was exam-
ined using actinomycin D (Act D) treatment in the presence
or absence of mammea E/BB. The results demonstrated
that mammea E/BB treatment did not significantly alter the
decay of WT1 mRNA. Collectively, the results strongly sug-
gest that WT1 repression by mammea E/BB is not through
accelerated WT1 protein or mRNA degradation but rather
is related to the WT1 signaling pathway.
The experiment further examined whether mammea
E/BB impacts the transcriptional regulation in signal
transduction of the WT1 gene using the ChIP assay. It
was found that treatment of K562 cells with mammea E/
BB for 72 h could significantly inhibit WT1 binding to
its own promoter by 75 %. WT1 is known to drive its
own transcription using an auto-regulatory mechanism.
Mammea E/BB also disrupted c-Fos binding to the WT1
promoter. C-Fos/AP-1 is the heterodimeric partner of c-
Jun, together creating the AP-1 transcription factor. AP-
1 is known to play an important role in cell proliferation
[29] and the WT1 promoter has one AP-1 consensus se-
quence, TGAGTGA, at +144 to +150. C-Fos/AP-1 must
be phosphorylated by MAPK/ERK in order to function
as a transcription factor [30] and mammea E/BB may in-
hibit c-Fos/AP-1 recruitment to the WT promoter by
inhibiting ERK1/2 phosphorylation (discussed below).
The minimal promoter element that is essential for WT1
gene expression is the WT1 proximal promoter (-301 bp)
[20]. The WT1 consensus binding site (-50 to -39) is in-
cluded in this proximal promoter element. Transfection of
this 301 bp construct, contained within the pGL3 reporter
vector into K562 cells demonstrated high luciferase activity
with vehicle control treated cells and a diminished re-
sponse with the various concentrations of mammea E/BB
(1.5, 2.5, and 3.5 μM). As a control, a reporter construct
containing a mutated WT1 binding site was included. The
mutant vector did not show significantly increased activity
compared to the empty pGL3 vector, demonstrating that
this assay is mostly driven by WT1 binding.
Mammea E/BB had varying effects on WT1 signaling
in K562 cells and led to a significant decrease in p-
ERK1/2 phosphorylation. Given the wide-ranging roles
for ERK1/2 in cell proliferation and survival, inhibition
of ERK1/2 phosphorylation may contribute to mammea
E/BB’s biological activity. These findings demonstrate
that mammea E/BB decreased WT1 protein expression
and induced S phase cell cycle arrest in leukemia cells.
This study uses an in vitro experimental model and will
be further studied in an animal models and clinical
trials. In the previous study, WT1 expression in patient
leukemic cells was determined after turmeric curcumin
treatment and WT1 mRNA was decreased after
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treatment, especially in patients with a high level of
WT1 gene expression patients [31].
Conclusion
The current study has demonstrated that pure mammea
E/BB-mediated down-regulation of WT1 was not the re-
sult of protein or mRNA degradation processes. Rather,
both chromatin immunoprecipitation (ChIP) and lucifer-
ase reporter assays indicate that mammea E/BB interferes
with WT1 and c-Fos/AP-1 binding to their DNA consen-
sus sites at the proximal promoter of the WT1 gene, nulli-
fying WT1’s positive auto-regulatory role. Therefore, a
low dose of mammea E/BB functions to inhibit WT1 ex-
pression at the transcriptional regulatory level and induce
S phase cell cycle arrest in K562 cells. This novel mechan-
istic knowledge of how mammea E/BB affects WT1 tran-
scriptional function in leukemic cells may be useful in the
future development of the natural product for therapeutic
treatment of leukemia patients.
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